Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 4Colorectal Neoplasms 3Rectal Neoplasms 1Pancreatitis 1Pancreatic Diseases 1Ovarian Neoplasms 1Esophageal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Adenoma, Islet Cell 1

Interventions

pembrolizumab 25Nivolumab 20atezolizumab 8Magnetic Resonance Spectroscopy 7Ipilimumab 7Specimen Handling 5Paclitaxel 5Fluorodeoxyglucose F18 4Cyclophosphamide 4Carboplatin 4fludarabine 3durvalumab 3avelumab 3Interleukin-2 3Gemcitabine 3Docetaxel 3130-nm albumin-bound paclitaxel 3tislelizumab 2spartalizumab 2regorafenib 2epacadostat 2cabozantinib 2aldesleukin 2Taxes 2Pemetrexed 2FAPI-46 2Cisplatin 2Albumin-Bound Paclitaxel 2zanidatamab 1veliparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × Histocompatibility Testing × Gastrointestinal × Clear all
NCT03794128 2020-09-11

A Study of Personalized Neoantigen Cancer Vaccines

Gritstone bio, Inc.

Completed
93 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡